Hair Stimulating Complex (HSC)
Launched in 2007, Histogen, Inc. continues to redefine and distinguish regenerative medicine in its development of innovative products without using animals or embryonic stem cells. Histogen’s CEO, Dr. Gail Naughton, has extensively researched tissue engineering for nearly two decades and holds more than 90 patents in the field. The company uses proprietary bioreactors that emulate an embryonic environment where newly created fibroblasts organically produce growth factors and vital proteins from which Histogen’s laboratories continue to develop its vast portfolio of life-changing products including Hair Stimulating Complex (HSC) for hair regrowth. Dr. Craig Ziering serves as the lead investigator of clinic trials for HSC. Not only has he found no adverse effects from the product’s clinical trials, but he has also noted that trials of the products have produced more hair with thicker hair shafts as well as completely new hair follicles in the areas treated with HSC.
In May 2011 Histogen’s Dr. Jonathan Mansbridge presents “Clinical evaluation of hypoxic fibroblast secreted proteins to induce hair growth in androgenetic alopecia” at the World Congress of Dermatology in Seoul, Korea. Pan-Asian approval for HSC is estimated for 2014, with an introduction of the injectable hair regrowth product to the United States market soon after in 2015. There is potential for an earlier launch of the product in other particular identified countries.
Some of the numerous other events that are part of Histogen’s revolutionary research include:
January 2011: Presentation of data at the 5th Annual Stem Cells and Regenerative Medicine World Congress. Histogen shared their findings on various embryonic matrix proteins have been associated with the reversion of cancer cell phenotype, as well as follistatin, which is known to induce apoptosis in cancer cells. Histogen’s research has revealed certain processes that inhibit rapidly dividing cancer cell growth as well as stimulate stem cell growth.
June 2010: Introduction of research results at the International Society for Stem Cell Research (ISSCR) Annual Meeting in which human extracellular matrix (hECM), when produced under proprietary conditions of hypoxia and suspension demonstrated the ability eliminate or reduce the tumor load in colon cancer, melanoma and breast cancer.